热门资讯> 正文
Zevra股价在FDA关于阿尼莫的会议前上涨16%
2024-08-01 02:49
- Shares of Zevra (NASDAQ:ZVRA) climbed 16% Wednesday ahead of an FDA advisory committee meeting on Friday that will discuss the company’s resubmitted market application for arimoclomol.
- The Danish company is seeking to have the product approved for the treatment of adults and pediatric patients two years of age or older with Niemann-Pick disease type C.
- Zevra (ZVRA) resubmitted the application in December 2023. The FDA declined to approve the product in June 2021, issuing a Complete Response Letter to the product’s former owner, Orphazyme. Zevra (ZVRA) acquired arimoclomol in May 2022.
- The FDA is expected to issue a decision on whether to approve the therapy by Sept. 21.
- Zevra (ZVRA) was formerly known as KemPharm.
More on Zevra Therapeutics
- Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
- Zevra Therapeutics rises as director buys $60K in company shares
- Zevra announces FDA meeting to review its Niemann-Pick disease type C treatment drug
- Seeking Alpha’s Quant Rating on Zevra Therapeutics
- Historical earnings data for Zevra Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
